glp 1 agonist in heart failure The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Treatment of High-Risk Patients with
Description
Market Growth The global GLP-1 drugs market size was US$ 48.3 billion in 2024 and is forecast to increase to US$ 52.95 billion by 2025
Twenty-five units from a 20mg/ml vial is 5mg
Jastreboff AM et al
These drugs work as appetite suppressants, helping patients regulate food intake by reducing feelings of hunger, and they are one of few medications able to reliably induce long-run weight loss and its downstream health benefits
Because peace of mind matters
Novo Nordisk went on to develop the longer-lasting semaglutide (Ozempic): a once-weekly injection that was approved for treatment of T2D in 2017
